Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
EVENITY (Amgen Australia Pty Ltd)
Product name
EVENITY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
239 working days (255)
Active ingredients
romosozumab
Registration type
NCE/NBE
Indication
EVENITY (solution for injection) is indicated for:
- The treatment of osteoporosis in postmenopausal women at high risk of fracture (see Section 5.1 Pharmacodynamic properties, Clinical trials).
- Treatment to increase bone mass in men with osteoporosis at high risk of fracture.